<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Trials comparing direct oral anticoagulants versus warfarin in atrial fibrillation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Trials comparing direct oral anticoagulants versus warfarin in atrial fibrillation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Trials comparing direct oral anticoagulants versus warfarin in atrial fibrillation</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="10%"></colgroup><colgroup span="2" width="5%"></colgroup><colgroup width="10%"></colgroup><colgroup span="2" width="5%"></colgroup><colgroup width="10%"></colgroup><colgroup span="2" width="5%"></colgroup><colgroup width="10%"></colgroup><colgroup span="2" width="5%"></colgroup><colgroup width="10%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Trial</td> <td class="subtitle1" rowspan="2">N</td> <td class="subtitle1" colspan="3">Baseline characteristics of trial participants</td> <td class="subtitle1" colspan="8">Trial details</td> <td class="subtitle1" rowspan="2">Median follow-up</td> </tr> <tr> <td class="subtitle2" colspan="2">Mean CHADS<sub>2</sub> score</td> <td class="subtitle2">Percent on aspirin</td> <td class="subtitle2" colspan="3">Study drug (DOAC) and dose</td> <td class="subtitle2" colspan="3">Comparison</td> <td class="subtitle2" colspan="2">Mean percent time in INR range</td> </tr> <tr> <td>RE-LY</td> <td class="centered">18,113</td> <td class="centered" colspan="2">2.1</td> <td class="centered">40%</td> <td colspan="3">Dabigatran 110 mg twice daily or 150 mg twice daily</td> <td colspan="3">Warfarin (target INR 2.0 to 3.0)</td> <td class="centered" colspan="2">64%</td> <td class="centered">2 years</td> </tr> <tr> <td>ROCKET-AF</td> <td class="centered">14,264</td> <td class="centered" colspan="2">3.5</td> <td class="centered">36%</td> <td colspan="3">Rivaroxaban 20 mg once daily*</td> <td colspan="3">Warfarin (target INR 2.0 to 3.0)</td> <td class="centered" colspan="2">55%</td> <td class="centered">1.9 years</td> </tr> <tr> <td>ARISTOTLE</td> <td class="centered">18,201</td> <td class="centered" colspan="2">2.1</td> <td class="centered">31%</td> <td colspan="3">Apixaban 5 mg twice daily<sup>¶</sup></td> <td colspan="3">Warfarin (target INR 2.0 to 3.0)</td> <td class="centered" colspan="2">62%</td> <td class="centered">1.8 years</td> </tr> <tr class="divider_bottom"> <td>ENGAGE AF-TIMI 48</td> <td class="centered">21,105</td> <td class="centered" colspan="2">2.8</td> <td class="centered">29%</td> <td colspan="3">Edoxaban<sup>Δ</sup> 30 mg once daily or 60 mg once daily</td> <td colspan="3">Warfarin (target INR 2.0 to 3.0)</td> <td class="centered" colspan="2">65%</td> <td class="centered">2.8 years</td> </tr> <tr> <td class="subtitle1" colspan="2" rowspan="3">Trial</td> <td class="subtitle1" colspan="12">Event rates<sup>◊</sup> for key outcomes</td> </tr> <tr> <td class="subtitle2" colspan="3">Death</td> <td class="subtitle2" colspan="3">Stroke or systemic embolic event</td> <td class="subtitle2" colspan="3">Hemorrhagic stroke</td> <td class="subtitle2" colspan="3">Major bleeding<sup>§</sup></td> </tr> <tr> <td class="subtitle3">DOAC</td> <td class="subtitle3">Warfarin</td> <td class="subtitle3">Relative effect (95% CI)</td> <td class="subtitle3">DOAC</td> <td class="subtitle3">Warfarin</td> <td class="subtitle3">Relative effect (95% CI)</td> <td class="subtitle3">DOAC</td> <td class="subtitle3">Warfarin</td> <td class="subtitle3">Relative effect (95% CI)</td> <td class="subtitle3">DOAC</td> <td class="subtitle3">Warfarin</td> <td class="subtitle3">Relative effect (95% CI)</td> </tr> <tr> <td rowspan="2">RE-LY</td> <td class="centered">110 mg</td> <td class="centered">3.75</td> <td class="centered">4.13</td> <td class="centered">RR 0.91 (0.8-1.03)</td> <td class="centered">1.53</td> <td class="centered">1.69</td> <td class="centered">RR 0.91 (0.74-1.11)</td> <td class="centered">0.12</td> <td class="centered">0.38</td> <td class="centered">RR 0.31 (0.17-0.56)</td> <td class="centered">2.71</td> <td class="centered">3.36</td> <td class="centered">RR 0.80 (0.69-0.93)</td> </tr> <tr> <td class="centered">150 mg</td> <td class="centered">3.64</td> <td class="centered">4.13</td> <td class="centered">RR 0.88 (0.77-1.00)</td> <td class="centered">1.11</td> <td class="centered">1.69</td> <td class="centered">RR 0.66 (0.53-0.82)</td> <td class="centered">0.10</td> <td class="centered">0.38</td> <td class="centered">RR 0.26 (0.14-0.49)</td> <td class="centered">3.11</td> <td class="centered">3.36</td> <td class="centered">RR 0.93 (0.81-1.07)</td> </tr> <tr> <td colspan="2">ROCKET-AF</td> <td class="centered">4.5</td> <td class="centered">4.9</td> <td class="centered">HR 0.92 (0.82-1.03)</td> <td class="centered">2.1</td> <td class="centered">2.4</td> <td class="centered">HR 0.88 (0.75-1.03)</td> <td class="centered">0.26</td> <td class="centered">0.44</td> <td class="centered">HR 0.59 (0.37-0.93)<sup>¥</sup></td> <td class="centered">3.6</td> <td class="centered">3.4</td> <td class="centered">HR 1.04 (0.9-1.2)<sup>¥</sup></td> </tr> <tr> <td colspan="2">ARISTOTLE</td> <td class="centered">3.52</td> <td class="centered">3.94</td> <td class="centered">HR 0.89 (0.80-0.998)</td> <td class="centered">1.27</td> <td class="centered">1.60</td> <td class="centered">HR 0.79 (0.66-0.95)</td> <td class="centered">0.24</td> <td class="centered">0.47</td> <td class="centered">HR 0.51 (0.35-0.75)</td> <td class="centered">2.13</td> <td class="centered">3.09</td> <td class="centered">HR 0.69 (0.6-0.8)</td> </tr> <tr> <td>ENGAGE AF-TIMI 48</td> <td class="centered">30 mg</td> <td class="centered">3.80</td> <td class="centered">4.35</td> <td class="centered">HR 0.87 (0.79-0.96)</td> <td class="centered">2.04</td> <td class="centered">1.80</td> <td class="centered">HR 1.13 (0.96-1.34)</td> <td class="centered">0.16</td> <td class="centered">0.47</td> <td class="centered">HR 0.33 (0.22-0.50)</td> <td class="centered">1.61</td> <td class="centered">3.43</td> <td class="centered">HR 0.47 (0.41-0.55)</td> </tr> <tr> <td>ENGAGE AF-TIMI 48</td> <td class="centered">60 mg</td> <td class="centered">3.99</td> <td class="centered">4.35</td> <td class="centered">HR 0.92 (0.83-1.01)</td> <td class="centered">1.57</td> <td class="centered">1.80</td> <td class="centered">HR 0.87 (0.73-1.04)</td> <td class="centered">0.26</td> <td class="centered">0.47</td> <td class="centered">HR 0.54 (0.38-0.77)</td> <td class="centered">2.75</td> <td class="centered">3.43</td> <td class="centered">HR 0.80 (0.71-0.91)</td> </tr> <tr> <td colspan="2">Combined results<sup>‡</sup></td> <td class="centered">6.90</td> <td class="centered">7.68</td> <td class="centered">RR 0.90 (0.85-0.95)</td> <td class="centered">3.11</td> <td class="centered">3.79</td> <td class="centered">RR 0.81 (0.73-0.91)</td> <td class="centered">0.44</td> <td class="centered">0.90</td> <td class="centered">RR 0.49 (0.38-0.64)</td> <td class="centered">5.26</td> <td class="centered">6.17</td> <td class="centered">RR 0.86 (0.73-1.0)</td> </tr> </tbody></table></div><div class="graphic_footnotes">DOAC: direct oral anticoagulant; AF: atrial fibrillation; N: number of trial participants; CHADS<sub>2</sub>: score to estimate risk of stroke with 1 point assigned for each of the following clinical features: history of congestive heart failure, hypertension, age ≥75 years, or diabetes mellitus, and 2 points assigned for prior stroke or transient ischemic attack; INR: international normalized ratio; HR: hazard ratio; RR: relative risk.<br/>* Dose of rivaroxaban was adjusted to 15 mg once daily for renal insufficiency (creatinine clearance 30 to 49 mL/minute [0.5 to 0.82 mL/second]).<br/>¶ Dose of apixaban was adjusted to 2.5 mg twice daily for patients with two or more of: age ≥80 years, body weight ≤60 kg, or renal insufficiency (serum creatinine level ≥1.5 mg/dL [133 micromol/L]).<br/>Δ For patients in either dose group, the dose of edoxaban was reduced by 50% if any of the following characteristics were present: estimated creatinine clearance 30 to 50 mL/minute, body weight ≤60 kg, or concomitant use of verapamil, quinidine, or dronedarone.<br/>◊ For the individual trials, the annual event rate (expressed as %/year) is presented for each outcome. For the meta-analysis, the table provides the absolute event rates (%) during the total study duration, which varied between studies (median follow-up 1.8 to 2.8 years).<br/>§ Major bleeding was variably defined. In RE-LY, it was defined as a reduction in hemoglobin of at least 2 g/dL [20 g/L], transfusion of ≥2 units of blood, or symptomatic bleeding in a critical area or organ. In ROCKET-AF, ARISTOTLE, and ENGAGE AF-TIMI 48, it was defined as fatal bleeding, bleeding at a critical site, or overt bleeding plus fall in hemoglobin of at least 2 g/dL [20 g/L] or transfusion of ≥2 units of blood.<br/>¥ For ROCKET-AF, the results for hemorrhagic stroke and for bleeding are based on an as-treated safety population.<br/>‡ These combined results include data for dabigatran 150 mg twice daily, rivaroxaban 20 mg once daily, apixaban 5 mg twice daily, and edoxaban 60 mg once daily.</div><div class="graphic_reference">Data from: 

<ol>
<li>Connolly SJ, Ezekowitz MD, Eikelbloom YS, et al. Dabigatran versus warfarin in patients with atrial fibrillation; N Engl J Med 2009; 361:1139.</li>
<li>Patel MR, Mahaffey KE, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation; N Engl J Med 2011; 365:883.</li>
<li>Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation; N Engl J Med 2011; 365:981.</li>
<li>Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369:2093.</li>
<li>Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955.</li></ol></div><div id="graphicVersion">Graphic 131871 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
